<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432234</url>
  </required_header>
  <id_info>
    <org_study_id>PI15/0157 (2015607)</org_study_id>
    <nct_id>NCT03432234</nct_id>
  </id_info>
  <brief_title>Respiratory Microbiome and COPD Exacerbations (RESMECOPD)</brief_title>
  <acronym>RESMECOPD</acronym>
  <official_title>Respiratory Microbiome and COPD Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Genomic Regulation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global objective of this coordinated project is to test the following hypotheses: 1) the
      lung microbiome in chronic obstructive pulmonary disease (COPD) is different in patients
      suffering from frequent exacerbations (FE) compared those who do not (NE ); 2) The microbial
      profile of patients with FE is associated with a different local and systemic inflammatory
      pattern; and 3) the inflammatory and immune characteristics of COPD are modulated by the
      intestinal microbiome.

      The project is based on bronchoalveolar lavage (BAL) for sampling lung microbiome, and
      includes analysis of regional variability (intrapulmonary) and temporal variability. The
      project will also assess the correlation between BAL samples obtained from the proximal
      airway (oral cavity, oropharynx and sputum), and the representation of lung microbiome in
      them. A cohort of COPD patients (n = 50 FE; n = 50 NE) and healthy subjects (n= 30), matched
      by age, sex and tobacco consumption. Respiratory secretion samples will be collected in
      clinical stability samples, with resampling in a quarter of the participants at 6-9 months.
      Coordinator Project: Bacterial and fungal microbiota will be determined by 16S rRNA and ITS
      amplification and sequencing. Virome and functional metagenomics will be analyzed in a
      quarter of the participants. Subprojects: Regional variability in the lung, local and
      systemic inflammatory response, and the relationship between the intestinal microbiome and
      inflammatory and clinical characteristics of the disease will be determined. The integration
      of the results will be performed using network medicine methodologies. The results of this
      project will help to understand the pathogenesis of COPD and its exacerbations with the final
      aim to identify new therapeutic targets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Respiratory Microbiome in COPD patients with FE and NE.</measure>
    <time_frame>7 days</time_frame>
    <description>Respiratory Microbiome composition will be determined by using metagenomic aproaches.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteria related to pulmonary and systemic inflamatory factors (FE vs NE)</measure>
    <time_frame>7 days</time_frame>
    <description>Determination of pulmonary and systemic markers with ELISA kit. Microbiome will be determined by metagenomic techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal variability of respiratory microbiome in COPD patients (FE vs NE).</measure>
    <time_frame>12 months</time_frame>
    <description>Change of respiratory Microbiome (diversity and abundance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inmunological response of lung epithelial cells COPD patients after an infectious and inflammatory stimuli</measure>
    <time_frame>7 days</time_frame>
    <description>The in vitro response of epithelial cells will be determined with ELISA kits.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Spatial variability of respiratory microbiome in COPD patients (FE vs NE).</measure>
    <time_frame>1 day</time_frame>
    <description>Respiratory Microbiome Composition of different types of samples.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Exacerbation COPD</condition>
  <arm_group>
    <arm_group_label>COPD and frequent exacerbation</arm_group_label>
    <description>Patient with COPD diagnosis and at least two exacerbations by year (FE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD no frequent exacerbation</arm_group_label>
    <description>Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy (control)</arm_group_label>
    <description>Healthy volunteers patients (H)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarkers</intervention_name>
    <description>This is an observational study, there is no intervention</description>
    <arm_group_label>COPD and frequent exacerbation</arm_group_label>
    <arm_group_label>COPD no frequent exacerbation</arm_group_label>
    <arm_group_label>Healthy (control)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oral Wash, oropharingeal swab, sputum, brochoalveolar lavage, feces, plasma, serum, white
      blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects were COPD patients GOLD II/III in stable situation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spirometry: FEV1/FVC &lt; 70%; FEV1 between 50 and 80% predicted (GOLD II/III)

          -  Clinical Stability (no therapeutic change and/or use of antibiotics) during 8 weeks. -
             The treatment received will be registered for post-hoc studies stratified by this
             condition.

        Exclusion Criteria:

          -  Drug addiction, alcohol abuse,

          -  Use of long-term oral or nebulised antibiotic therapy.

          -  History of allergies, asthma or other chronic respiratory disease, sanitary worker,
             working exposure to dust or fumes.

          -  Other diseases: Severe cardiovascular, neurological, psychiatric, renal, hepatic or
             gastrointestinal , that might interfere with the daily life activities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriol Sibila</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Faner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Monso</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Parc Tauli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduard Monso</last_name>
    <phone>937231010</phone>
    <email>emonso@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marian Garcia-Nuñez</last_name>
    <phone>937231010</phone>
    <phone_ext>22064</phone_ext>
    <email>mgarcianu@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Garcia</last_name>
      <email>mgarcianu@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Marin</last_name>
      <email>aliziamarin@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Marian Garcia</last_name>
      <email>mgarcia@igtp.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Faner</last_name>
      <email>RFANER@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Alvar Agusti</last_name>
      <email>alvar.agusti@clinic.ub.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Dorca</last_name>
      <email>jodorca@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisol Dominguez</last_name>
      <email>mdominguez@parcdesalutmar.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hosptial de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Sibila</last_name>
      <email>OSibila@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Eduard Monsó-Molas</investigator_full_name>
    <investigator_title>Head of Respiratory Medicine Department</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Sequencing data will be available in public databases.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

